The global injectable-focused company Gland Pharma faced multiple headwinds, such as supply chain disruptions, cost escalation and shutdown of insulin line, in the first quarter of 2022-23. This has impacted the revenue, EBITDA and PAT which declined 26%, 38% and 34.6% on a y-o-y basis, respectively. Despite this, analysts remain confident about the company’s future growth for multiple reasons.

First, the growth of injectables has been among